Several studies have suggested that using acute phase inflammatory markers, such as ESR and PTX-3 are non-invasive, safe, and available methods to reflect disease activity in patients with IBD [9, 11, 12, 15]. The gene discussed is PTX3; the disease is inflammatory bowel disease.